These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29624472)

  • 1. Efficacy and safety of baroreflex activation therapy for treatment of resistant hypertension: a systematic review and meta-analysis.
    Chunbin W; Fu S; Jing H
    Clin Exp Hypertens; 2018; 40(6):501-508. PubMed ID: 29624472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension.
    Wallbach M; Lehnig LY; Schroer C; Lüders S; Böhning E; Müller GA; Wachter R; Koziolek MJ
    Hypertension; 2016 Apr; 67(4):701-9. PubMed ID: 26902491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system.
    Wallbach M; Born E; Kämpfer D; Lüders S; Müller GA; Wachter R; Koziolek MJ
    Clin Res Cardiol; 2020 Apr; 109(4):513-522. PubMed ID: 31388741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review.
    Courand PY; Feugier P; Workineh S; Harbaoui B; Bricca G; Lantelme P
    Arch Cardiovasc Dis; 2014 Dec; 107(12):690-6. PubMed ID: 25445751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension.
    Halbach M; Hickethier T; Madershahian N; Reuter H; Brandt MC; Hoppe UC; Müller-Ehmsen J
    J Hypertens; 2015 Aug; 33(8):1697-703. PubMed ID: 26107267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.
    Bisognano JD; Bakris G; Nadim MK; Sanchez L; Kroon AA; Schafer J; de Leeuw PW; Sica DA
    J Am Coll Cardiol; 2011 Aug; 58(7):765-73. PubMed ID: 21816315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of baroreflex activation therapy on blood pressure and sympathetic function in patients with refractory hypertension: the rationale and design of the Nordic BAT study.
    Gordin D; Fadl Elmula FEM; Andersson B; Gottsäter A; Elf J; Kahan T; Christensen KL; Vikatmaa P; Vikatmaa L; Bastholm Olesen T; Groop PH; Olsen MH; Tikkanen I;
    Blood Press; 2017 Oct; 26(5):294-302. PubMed ID: 28595464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension.
    Wallbach M; Böhning E; Lehnig LY; Schroer C; Müller GA; Wachter R; Lüders S; Zenker D; Koziolek MJ
    J Hypertens; 2018 Aug; 36(8):1762-1769. PubMed ID: 29677053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carotid baroreceptor stimulation on retinal arteriole remodeling evaluated with adaptive optics camera in resistant hypertensive patients.
    Gallo A; Rosenbaum D; Kanagasabapathy C; Girerd X
    Ann Cardiol Angeiol (Paris); 2017 Jun; 66(3):165-170. PubMed ID: 28554698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?
    Bolignano D; Coppolino G
    Rev Cardiovasc Med; 2018 Sep; 19(3):89-95. PubMed ID: 31054557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].
    Wallbach M; Koziolek MJ; Wachter R
    Internist (Berl); 2018 Oct; 59(10):1011-1020. PubMed ID: 30182192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials.
    Wang C; Xiong B; Huang J
    Heart Lung Circ; 2016 Oct; 25(10):1021-30. PubMed ID: 27118266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.
    Hoppe UC; Brandt MC; Wachter R; Beige J; Rump LC; Kroon AA; Cates AW; Lovett EG; Haller H
    J Am Soc Hypertens; 2012; 6(4):270-6. PubMed ID: 22694986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.
    de Leeuw PW; Bisognano JD; Bakris GL; Nadim MK; Haller H; Kroon AA;
    Hypertension; 2017 May; 69(5):836-843. PubMed ID: 28320856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension.
    Alnima T; Scheffers I; De Leeuw PW; Winkens B; Jongen-Vancraybex H; Tordoir JH; Schmidli J; Mohaupt MG; Allemann Y; Kroon AA
    J Hypertens; 2012 Aug; 30(8):1665-70. PubMed ID: 22728906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baroreceptor Stimulation for Resistant Hypertension.
    Yoruk A; Bisognano JD; Gassler JP
    Am J Hypertens; 2016 Dec; 29(12):1319-1324. PubMed ID: 27444637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue baroreflex activation therapy after Stanford B aortic dissection due to therapy-refractory hypertension.
    Weipert KF; Most A; Dörr O; Helmig I; Elzien M; Krombach G; Hamm CW; Erkapic D; Schmitt J
    J Am Soc Hypertens; 2016 Jun; 10(6):490-2. PubMed ID: 27184290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems.
    Wachter R; Halbach M; Bakris GL; Bisognano JD; Haller H; Beige J; Kroon AA; Nadim MK; Lovett EG; Schafer JE; de Leeuw PW
    J Am Soc Hypertens; 2017 Feb; 11(2):81-91. PubMed ID: 28065708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.
    Bakris GL; Nadim MK; Haller H; Lovett EG; Schafer JE; Bisognano JD
    J Am Soc Hypertens; 2012; 6(2):152-8. PubMed ID: 22341199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial.
    Ursoniu S; Sahebkar A; Andrica F; Serban C; Banach M;
    Clin Nutr; 2016 Jun; 35(3):615-25. PubMed ID: 26071633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.